Search
Tucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalTucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. … [L12951] Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.[L12945]
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsFlorbetapir F-18
go.drugbank.com/drugs/DB09149ApprovedInvestigationalFlorbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide … Marketed as the product Amyvid, florbetapir 18F is indicated for positron emission tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment
Synonyms: 4-{(E)-2-[6-(2-{2-[2-(18F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-N-methylaniline, Florbetapir F-18Cedazuridine
go.drugbank.com/drugs/DB15694ApprovedInvestigationalMyelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias progressing to secondary acute myeloid leukemia (sAML), which is invariably fatal if untreated … [A215107, A215112, A215117, A215127] Cedazuridine is a fluorinated tetrahydrouridine derivative specifically designed to inhibit CDA and facilitate oral administration of hypomethylating agents.
Categories: Heterocyclic Compounds, 1-RingSynonyms: (4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridineImetelstat
go.drugbank.com/drugs/DB14909ApprovedInvestigationalImetelstat is a first-in-class 18-amino acid oligonucleotide that directly and competitively inhibits human telomerase. … [A263973] It is used to treat anemia in patients with myelodysplastic syndromes (MDS), a group of hematologic disorders characterized by ineffective hematopoiesis, peripheral cytopenia, abnormal marrow
Zongertinib
go.drugbank.com/drugs/DB18762ApprovedInvestigationalZongertinib is a selective, irreversible tyrosine kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2). … [L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingLinerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). … [L56127] PBC is a rare, chronic autoimmune liver disease characterized by the destruction of small bile ducts, leading to cholestasis and the systemic accumulation of bile acids, which are hypothesized
Categories: Cytochrome P-450 CYP3A Inhibitors, Heterocyclic Compounds, 1-RingSynonyms: 3-((((3R,5R)-3-BUTYL-3-ETHYL-7-METHOXY-1,1-DIOXO-5-PHENYL-2,3,4,5-TETRAHYDRO- 1H-1.LAMBDA.6,4-BENZOTHIAZEPIN-8-YL)METHYL)AMINO)PENTANEDIOIC ACID, PENTANEDIOIC ACID, 3-((((3R,5R)-3-BUTYL-3-ETHYL-2,3,4,5-TETRAHYDRO-7-METHOXY-1,1-DIOXIDO-5-PHENYL-1,4-BENZOTHIAZEPIN-8-YL)METHYL)AMINO)-Ergotamine
go.drugbank.com/drugs/DB00696ApprovedA vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.
Mixtures: FENCAFEN®TABLETAS, MIGRADOL® TABLETACategories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, P-glycoprotein inhibitorsCarisoprodol
go.drugbank.com/drugs/DB00395ApprovedThis drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine [FDA label, F4060, F4069]. … Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesSynonyms: (RS)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate, N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamateColfosceril palmitate
go.drugbank.com/drugs/DB09114ApprovedWithdrawnColfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome. … [T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.[L1109] Nowadays colfosceril palmitate is under the state of canceled post-marketing.
Peginesatide
go.drugbank.com/drugs/DB08894ApprovedWithdrawnChemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. … Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life.
Categories: Compounds used in a research, industrial, or household setting